首页> 外国专利> CELL PERMEABLE INHIBITORS OF THE SCAFFOLD PROTEIN PLENTY OF SH3 DOMAINS (POSH) OR SH3RFL

CELL PERMEABLE INHIBITORS OF THE SCAFFOLD PROTEIN PLENTY OF SH3 DOMAINS (POSH) OR SH3RFL

机译:SH3域(POSH)或SH3RFL的支架蛋白的细胞透性抑制剂

摘要

Here, we identify Plenty of SH3 (POSH) and JNK-interacting protein 1 (JIP-1) as a multi-protein scaffold network for TCR-mediated JNK1 activation in CD8+ T-cells. Disruption of the POSH/JIP-1 complex led to profound defects in the activation of JNK1, as well as deficient activation or induction of the transcription factors c-Jun, T-bet and Eomesodermin. Furthermore, disruption of the POSH/JIP complex in CD8+ T-cells resulted in impaired proliferation, decreased cytokine expression and the inability to control tumors. Collectively, these data identify a mechanism for the specific regulation of TCR-dependent JNK1 activation and function that is key for CD8+ T-cell responses. The present invention describes a group of compounds that individually or in concert target a common set of biological pathways important in T cell function, activation of innate inflammation, ischemic reperfusion injury, HIV release and oncogenesis.
机译:在这里,我们确定大量的SH3(POSH)和JNK相互作用蛋白1(JIP-1)作为TCR介导JNK1在CD 8 + T细胞中激活的多蛋白支架网络。 POSH / JIP-1复合物的破坏导致JNK1激活中的严重缺陷,以及转录因子c-Jun,T-bet和Eomesodermin的激活或诱导不足。此外,CD8 + T细胞中POSH / JIP复合物的破坏导致增殖受损,细胞因子表达降低以及无法控制肿瘤。总体而言,这些数据确定了特定调节TCR依赖的JNK1激活和功能的机制,这是CD 8 + T细胞反应的关键。本发明描述了一组化合物,这些化合物单独地或共同地靶向在T细胞功能,先天性炎症的活化,缺血性再灌注损伤,HIV释放和致癌作用中重要的一组共同的生物途径。

著录项

  • 公开/公告号WO2015023824A2

    专利类型

  • 公开/公告日2015-02-19

    原文格式PDF

  • 申请/专利权人 THE CURATORS OF THE UNIVERSITY OF MISSOURI;

    申请/专利号WO2014US51019

  • 发明设计人 DANIELS MARK;

    申请日2014-08-14

  • 分类号A61K38/17;

  • 国家 WO

  • 入库时间 2022-08-21 15:08:14

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号